PURPOSE: The goal of the present study was to analyze long-term results of fractionated stereotactic radiotherapy (SRT) in patients with a meningioma. METHODS AND MATERIALS: A total of 72 patients treated between 1996 and 2008 in MAASTRO clinic (n = 45) and University Hospital Zurich (n = 27) were included. SRT was given as primary treatment (n = 46), postoperatively (n = 19) or at recurrence (n = 7); 49 tumours (68%) were located in the skull base. Median total dose was 54 Gy. RESULTS: Median follow-up was 4.13 years (range 0.66-11 years). The 3- and 5-year overall survival were 92 and 79% for grade 0 and I meningioma. Progression-free survival for grade 0 and I was 95% at 3 and 5 years, and 40% for grade II and III at 3 years. In 98.4% of patients, clinical symptoms were stable or improved. The majority of symptoms improved within 24 months after SRT. Local control is significantly better if patients are irradiated immediately after diagnosis compared to a watchful waiting policy (p = 0.017). Grade IV toxicity was low (4.2%, n = 3) CONCLUSION: SRT is an effective treatment with high local and clinical control. Early SRT resulted in better outcome than late treatment at progression.
PURPOSE: The goal of the present study was to analyze long-term results of fractionated stereotactic radiotherapy (SRT) in patients with a meningioma. METHODS AND MATERIALS: A total of 72 patients treated between 1996 and 2008 in MAASTRO clinic (n = 45) and University Hospital Zurich (n = 27) were included. SRT was given as primary treatment (n = 46), postoperatively (n = 19) or at recurrence (n = 7); 49 tumours (68%) were located in the skull base. Median total dose was 54 Gy. RESULTS: Median follow-up was 4.13 years (range 0.66-11 years). The 3- and 5-year overall survival were 92 and 79% for grade 0 and I meningioma. Progression-free survival for grade 0 and I was 95% at 3 and 5 years, and 40% for grade II and III at 3 years. In 98.4% of patients, clinical symptoms were stable or improved. The majority of symptoms improved within 24 months after SRT. Local control is significantly better if patients are irradiated immediately after diagnosis compared to a watchful waiting policy (p = 0.017). Grade IV toxicity was low (4.2%, n = 3) CONCLUSION: SRT is an effective treatment with high local and clinical control. Early SRT resulted in better outcome than late treatment at progression.
Authors: Dirk De Ruysscher; Diane Severin; Elizabeth Barnes; Michael Baumann; Rob Bristow; Vincent Grégoire; Tobias Hölscher; Theo Veninga; Andrzej Polański; Evert-Ben van Veen; Christine Verfaillie; Germaine Heeren; Sambasivarao Damaraju; Uwe Just; Karin Haustermans Journal: Radiother Oncol Date: 2010-03-24 Impact factor: 6.280
Authors: A Theelen; J Martens; G Bosmans; R Houben; J J Jager; I Rutten; P Lambin; A W Minken; B G Baumert Journal: Strahlenther Onkol Date: 2011-12-24 Impact factor: 3.621
Authors: J Debus; M Wuendrich; A Pirzkall; A Hoess; W Schlegel; I Zuna; R Engenhart-Cabillic; M Wannenmacher Journal: J Clin Oncol Date: 2001-08-01 Impact factor: 44.544
Authors: Ruud G J Wiggenraad; Anna L Petoukhova; Lia Versluis; Jan P C van Santvoort Journal: Int J Radiat Oncol Biol Phys Date: 2009-02-11 Impact factor: 7.038
Authors: R Jalali; C Loughrey; B Baumert; J Perks; A P Warrington; D Traish; S Ashley; M Brada Journal: Clin Oncol (R Coll Radiol) Date: 2002-04 Impact factor: 4.126
Authors: Kerstin A Kessel; Hanna Fischer; Markus Oechnser; Claus Zimmer; Bernhard Meyer; Stephanie E Combs Journal: Strahlenther Onkol Date: 2017-06-15 Impact factor: 3.621